Sharlene

Name： Sharlene Gill

Nationality: Canadian

Job Title： Professor, Department of Medical Oncology

Current Positions：

Visiting Professor, Sun Yat-Sen University Cancer Centre, Guangzhou

Associate Professor of Medicine, BC Cancer Agency, Vancouver, BC Canada

Research Interests:

- Colorectal Cancer

- Pancreatic Cancer

- Clinical Trials

Recent Honors and Awards:

2010-2012 Scientific Planning Committee, American Society of Clinical Oncology – Colorectal Track

2009 – present Member, NCI Intergroup Colon Cancer Taskforce (NCIC.CTG Representative)

2009 UBC Faculty of Medicine Merit Award

Membership in Professional Societies:

Fellow, Royal College of Physicians and Surgeons of Canada

Fellow, American College of Physicians

Member, GI Disease Site Executive – National Cancer Institute of Canada Clinical Trials

Member, American Society of Clinical Oncology

Education:

1992 - B.Sc. Pharmacy – University of British Columbia, Canada

1996 – Doctor of Medicine (M.D.), University of British Columbia, Canada

2001 – Internal Medicine and Medical Oncology subspecialty training, University of British Columbia & BC Cancer Agency, Vancouver, BC Canada

2003 – GI Oncology Research Fellowship, Mayo Clinic, Rochester MN, USA

2003 – Masters of Public Health – Harvard School of Public Health, Boston, MA USA

Positions Held:

2003 – present Medical Oncologist, BC Cancer Agency, Vancouver, GC

2007 – present Chair, British Columbia GI Tumour Group, Vancouver, BC

2003 – present Senior Scientist, BC Cancer Research Centre, Vancouver, BC

Main Publications:

Book Chapters

1. Gill S, Goldberg RM Colorectal Carcinoma: Adjuvant and Primary Chemotherapy, chapter 110 in Advanced Therapy in Gastroenterology and Liver Disease, 5th edition (editors: TM Bayless, AM Diehl) 2004

2. Goldberg RM, Gill S Cancer of The Gastrointestinal Tract, Chapter 16, Cancer: Principles & Practice of Oncology Review, 1st edition (editor: Ramaswamy, Govindan).2005

3. Gill S et al Cancer in Gastrointestinal Oncology – Therapeutic Principles (editors: Blanke, Talamonti and Roedel). 2010

49 Peer-reviewed publications and 51 Abstract proceedings since 2003

Peer-reviewed publications over the last 3 years:

1. Knox J, Gill S, Synold T, Biagi J, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E and Seymour L. Phase 2 trial of SB715992 in Advanced Hepatocellular Carcinoma – an NCIC.CTG Study. Investigational New Drugs, 2008 Jan15

2. Smiljanic S and Gill S, Patterns of Diagnosis for Colorectal Cancer: Screening Detected versus Symptomatic Presentation, Diseases of Colon & Rectum, 2008 Feb

3. Gill S and Sargent D. Using Individual Patient Data Analyses to Improve Our Understanding of Adjuvant Therapy in Colon Cancer: Review of the ACCENT Collaborative Group, Current Colorectal Cancer Reports, 2008 July; 4(3): 155-159

4. Renouf D, Kennecke H and Gill S Temporal Trends in Chemotherapy Utilization for Colorectal Cancer, Clinical Colorectal Cancer, Clinical Colorectal Cancer, Nov 2008, 7(6): 386-389

5. Courneya K, Booth CM, Gill S, O’Brien P, Vardy J, Friedenreich C, Au HJ, Brundage M, Tu D and Meyer R, The Colon Health and Life Long Exercise Change Trial (CHALLENGE) NCIC. C021 – A randomized trial of the National Cancer Institute of Canada Clinical trials Group, Current Oncology, Dec 2008, 15 (6): 8-16

6. Lim H, Gill S, Speers C, Melosky B, Barnett J, Fitzgerald C, O’Reilly S and Kennecke H. Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients with Metastatic Colorectal Cancer (MCRC): a Population Based Study, Journal of Oncology Practice, in press

7. Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem J, Verslype C, Schiethauer W, Shang A, Cosaert J and Moore M Bevacizumab in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer: A Randomized Phase III Trial, Journal of Clinical Oncology, 2009 May 1;27(13):2231-7

8. Chan T, Brown C, Ho C and Gill S. Primary Tumour Resection in Metastatic Colorectal Cancer, American Journal of Oncology, 2009 Aug 21 Epub ahead of print

9. Shomas D, Miller R, Gill S, Quevedo F, Haddock M and Donohue J etal. Intraperitoneal Treatment for Peritoneal Mucinous Carcinomatosis of Appendiceal Origin After Operative Management: Long-term Follow-up of the Mayo Clinic Experience, Annals of Surgery, 249(4) April 2009 588-595

10. Monzon J, Cremlin C, Armstrong L, Nuk J, Young S, Horsman D, Garbutt K, Bajdik C and Gill S, Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer’, Int J of Cancer, 2009 August 3 Epub ahead of print

11. Chan T, Brown C, Ho C and Gill S. Primary Tumour Resection in Metastatic Colorectal Cancer, American Journal of Oncology, 2009 Aug 21 Epub ahead of print

12. Belezny K, Levesque M and Gill S, Response to 5-fluorouracil in metastatic extramammary Paget’s disease of the scrotum presenting as pancytopenia and back pain, Current Oncology, 2009 Sep (16)5, 81-3

13. Cremlin C, Armstrong L, Gill S and Huntsman D. Identification of Lynch Syndrome Families in British Columbia, Canadian Journal of Gastroenterology, 2009 Nov;23(11):761-7.

14. Bardia A, Loprinzi C, Grothey A, Nelson G, Alberts S, Menon S, Thome S, Gill S and Sargent D Adjuvant Chemotherapy for resected Stage II and III Colon Cancer: Comparison of two widely used Prognostic Calculators. Seminars in Oncology, 37:39-46, 2010

15. Suen M, Salh B, Yoshida E, Weiss A and Gill S. Sorafenib, a new treatment for advanced Hepatocellular Carcinoma: The preliminary British Columbia experience. University of British Columbia Medical Journal, March 2010 1(2), 18-21

16. Cripps C, Gill S, Ahmed S, Colwell B, Dowden S, Kennecke H et al. Consensus Recommendations for the Use of Anti-EGFR Therapies for Metastatic Colorectal Cancer. Current Oncology, 2010 Nov; 17(6):39-45

17. Al Barrack J and Gill S, Presentation and Outcomes of Patients Age 30 years and younger with Colorectal Cancer: A 20 year retrospective review. Medical Oncology, 2010 Jul 31

18. Aubin F, Gill S, R. Burkes MD, B. Coldwell, S. Kamel-Reid PhD, S. Koski MD, A. Pollett, B. Samson MD, M. Tehfe MD, R. Wong MD, S.Young PhD, D. Soulières MD. Consensus recommendations for KRAS testing in metastatic colorectal cancer (mCRC): statement from a Canadian National Expert Group. Current Oncology Aug 2011

19. Renouf D, Moore M, Hedley D, Gill S, Jonker D, Chen E, Goel R, Southwood B, Gauthier I, Walsh L, McIntosh L, Seymour L. A Phase I/II Study of Saracatinib (AZD0530) in Combination with Gemcitabine in Advanced Pancreatic Cancer, Investigational New Drugs, 2010 Dec 18 (Epub ahead of print)

20. Gill S, Loprinzi C, Kennecke H, Grothey A, Alberts S, Nelson G, Woods R, Speers C, Bardia A, O’Connell M, and Sargent DJ Prognostic Web-based Models for Stage II and III Colon Cancer: a Population and Clinical Trials-based Validation of Numeracy and Adjuvant! Online, Cancer, 2011 March 1 (Epub ahead of print)

21. Sargent D, Resnick M, O’Myers M, Goldar-Najafi A, Clancy T, Gill S, O’Siemons G, Shi Q, Bot B, Wu T-T, Beaudry G, Hanice JF and Fradet Y, Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis, Annals of Surgical Oncology, 2011 May 1

22. Renouf D, Villa D, Gill S, Lim H, Blanke C and Kennecke H. Survival for Metastatic Colorectal Cancer in the Bevacizumab Era. Clinical Colorectal Cancer, 2011 June 1

23. Czaykowski P, Gill S, Kennecke H, Gordon V, Turner D. Adjuvant Chemotherapy for Stage III Colon Cancer: Does Timing Matter? Diseases of Colon and Rectum, 2011, Sept; 54(9): 1082-9

24. Gill S, Berry S, Biagi S, Butts C, Buyse M, Chen E, Jonker D, Maginean C, Samson B, Steward J, Thirlwell M, Wong R and Maroun J Progression free survival as a primary endpoint in clinical trials of metastatic colorectal cancer Current Oncology, Vol 18 (2011 Oct 18), S5-S10